ARS Pharmaceuticals Inc
SPRY7.590USD
+0.860+12.78%
收盘 11/21, 16:00（美东）报价延迟15分钟
750.23M总市值
亏损市盈率 TTM
关于 ARS Pharmaceuticals Inc 公司
ARS Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于开发 neffy，用于紧急治疗 I 型过敏反应，包括过敏反应。neffy 是一种专有的肾上腺素组合物，含有一种名为 Intravail 的吸收促进剂，可使 neffy 以小剂量、小剂量和鼻腔喷雾的形式提供类似注射的肾上腺素吸收。I 型过敏反应是可能危及生命的超敏反应，可能在接触过敏原几分钟内发生，需要立即治疗以缓解症状并防止进一步发展。
ARS Pharmaceuticals Inc简介
公司代码SPRY
公司名称ARS Pharmaceuticals Inc
上市日期Dec 04, 2020
CEOMr. Richard E. Lowenthal
员工数量155
证券类型Ordinary Share
年结日Dec 04
公司地址11682 El Camino Real, Suite 120
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92130
电话18587719307
网址https://ars-pharma.com/
公司代码SPRY
上市日期Dec 04, 2020
CEOMr. Richard E. Lowenthal
ARS Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
持股股东
持股股东
占比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
股东类型
持股股东
占比
Hedge Fund
22.20%
Investment Advisor/Hedge Fund
19.53%
Investment Advisor
16.81%
Venture Capital
15.19%
Individual Investor
11.94%
Private Equity
8.39%
Corporation
4.88%
Research Firm
3.80%
Insurance Company
0.59%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
10.94M
11.07%
+80.00K
+0.74%
Sep 29, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
7.61M
7.7%
-2.11M
-21.74%
Jul 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.93M
3.98%
+47.01K
+1.21%
Jun 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.25M
3.29%
-228.66K
-6.57%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ALPS Medical Breakthroughs ETF
0.62%
First Trust Small Cap Growth AlphaDEX Fund
0.32%
SPDR S&P Biotech ETF
0.31%
VictoryShares US Small Mid Cap Value Momentum ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
First Trust Small Cap Core Alphadex Fund
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Principal U.S. Small-Cap ETF
0.08%
First Trust Multicap Growth Alphadex Fund
0.07%
查看更多
ALPS Medical Breakthroughs ETF
占比0.62%
First Trust Small Cap Growth AlphaDEX Fund
占比0.32%
SPDR S&P Biotech ETF
占比0.31%
VictoryShares US Small Mid Cap Value Momentum ETF
占比0.18%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.17%
First Trust Small Cap Core Alphadex Fund
占比0.16%
Invesco Nasdaq Biotechnology ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
Principal U.S. Small-Cap ETF
占比0.08%
First Trust Multicap Growth Alphadex Fund
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
ARS Pharmaceuticals Inc的前五大股东是谁？
ARS Pharmaceuticals Inc 的前五大股东如下：
RA Capital Management, LP持有股份：10.94M，占总股份比例：11.07%。
OrbiMed Advisors, LLC持有股份：8.29M，占总股份比例：8.39%。
Deerfield Management Company, L.P.持有股份：7.61M，占总股份比例：7.70%。
Lowenthal (Richard E)持有股份：6.83M，占总股份比例：6.91%。
Pratik Shah Living Trust持有股份：4.82M，占总股份比例：4.88%。
RA Capital Management, LP持有股份：10.94M，占总股份比例：11.07%。
OrbiMed Advisors, LLC持有股份：8.29M，占总股份比例：8.39%。
Deerfield Management Company, L.P.持有股份：7.61M，占总股份比例：7.70%。
Lowenthal (Richard E)持有股份：6.83M，占总股份比例：6.91%。
Pratik Shah Living Trust持有股份：4.82M，占总股份比例：4.88%。
ARS Pharmaceuticals Inc的前三大股东类型是什么？
ARS Pharmaceuticals Inc 的前三大股东类型分别是：
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
有多少机构持有ARS Pharmaceuticals Inc(SPRY)的股份？
截至2025Q3，共有381家机构持有ARS Pharmaceuticals Inc的股份，合计持有的股份价值约为87.74M，占公司总股份的88.78%。与2025Q2相比，机构持股有所增加，增幅为-8.98%。
哪个业务部门对ARS Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对ARS Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
